Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
Part of paid clinical trials in Duarte, California.
- Sponsor
- Incyte Corporation
- Study ID
- NCT02614612
- Phase
- PHASE1
- Status
- Completed
Conditions
- Graft-versus-host Disease (GVHD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Itacitinib (200 mg) — DRUG
- Itacitinib (300 mg) — DRUG
- prednisone or methylprednisolone (corticosteroids) — DRUGAll subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
Study Details
To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).
Key Dates
- Start date
- Dec 31, 2015
- Status verified
- Mar 2019
- Primary completion
- Jun 30, 2016
- Completion
- Aug 31, 2018
Study Design
- Enrollment
- 31 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Itacitinib (200 mg)Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
- Experimental: Itacitinib (300 mg)Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)
Primary Outcome Measure
Assess safety and tolerability of study treatment as measured by the frequency and severity of adverse events and serious adverse events [ Time Frame: First dose of study drug to 30 days after the last dose of study drug ]
Locations (23)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Duarte | California | - | - |
| - | La Jolla | California | - | - |
| - | Los Angeles | California | - | - |
| - | Denver | Colorado | - | - |
| - | Coral Gables | Florida | - | - |
| - | Atlanta | Georgia | - | - |
| - | Chicago | Illinois | - | - |
| - | Kansas City | Kansas | - | - |
| - | Westwood | Kansas | - | - |
| - | New Orleans | Louisiana | - | - |
| - | Boston | Massachusetts | - | - |
| - | Detroit | Michigan | - | - |
| - | St Louis | Missouri | - | - |
| - | Omaha | Nebraska | - | - |
| - | New York | New York | - | - |
| - | Rochester | New York | - | - |
| - | Cincinnati | Ohio | - | - |
| - | Cleveland | Ohio | - | - |
| - | Portland | Oregon | - | - |
| - | Hershey | Pennsylvania | - | - |
| - | Pittsburgh | Pennsylvania | - | - |
| - | Nashville | Tennessee | - | - |
| - | San Antonio | Texas | - | - |
Related Studies
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)PHASE3 · Recruiting · Incyte Corporation · Palo Alto, California
- Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationPHASE2 · Recruiting · University of Nebraska · Omaha, Nebraska
- Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD PreventionPHASE2 · Recruiting · Milton S. Hershey Medical Center · Hershey, Pennsylvania